


## S-methyl-KE-298

## Chemical Properties

CAS No. : 143584-75-2  
 Formula: C<sub>13</sub>H<sub>16</sub>O<sub>3</sub>S  
 Molecular Weight: 252.33  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
 Actual storage temperature shall be subject to the COA.



## Biological Description

Description	S-methyl-KE-298 is the second main metabolite in plasma, is a methyl conjugate of deacetyl-KE-298. KE-298 inhibits matrix metalloproteinase (MMP-1) production from rheumatoid arthritis (RA) synovial cells.
Targets(IC50)	MMP, Drug Metabolite
In vitro	In vitro protein binding of S-methyl-KE-298 is high in rat (>97%), dog (>89%) and human plasma (>99%), respectively[2].

## Solubility Information

Solubility	DMSO: 100 mg/mL (396.31 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (15.85 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	3.9631 mL	19.8153 mL	39.6306 mL
5 mM	0.7926 mL	3.9631 mL	7.9261 mL
10 mM	0.3963 mL	1.9815 mL	3.9631 mL
50 mM	0.0793 mL	0.3963 mL	0.7926 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Yoshida H , Kohno Y , Endo H , et al. Identification of metabolites of KE-298, a new antirheumatic drug, and its physiological properties in rats.[J]. Biological & Pharmaceutical Bulletin, 1996, 19(3):424-9.

Honda S, et al. Expression of membrane-type 1 matrix metalloproteinase in rheumatoid synovial cells. Clin Exp Immunol. 2001 Oct;126(1):131-6.

Yoshida H , Kohno Y , Endo H , et al. Stereoselective disposition and chiral inversion of KE-298, a new antirheumatic drug, in rats[J]. Chirality, 2015, 9(1):22-28.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481